vs

Side-by-side financial comparison of Ascendis Pharma A/S (ASND) and CENTRUS ENERGY CORP (LEU). Click either name above to swap in a different company.

Ascendis Pharma A/S is the larger business by last-quarter revenue ($267.3M vs $146.2M, roughly 1.8× CENTRUS ENERGY CORP). On growth, Ascendis Pharma A/S posted the faster year-over-year revenue change (42.3% vs -3.6%). Over the past eight quarters, CENTRUS ENERGY CORP's revenue compounded faster (82.9% CAGR vs 60.7%).

Growth hormone therapy refers to the use of growth hormone (GH) as a prescription medication—it is one form of hormone therapy. Growth hormone is a peptide hormone secreted by the pituitary gland that stimulates growth and cell reproduction. In the past, growth hormone was extracted from human pituitary glands. Growth hormone is now produced by recombinant DNA technology and is prescribed for a variety of reasons. GH therapy has been a focus of social and ethical controversies for 50 years.

Centrus Energy Corp. is an American company that supplies nuclear fuel for use in nuclear power plants and works to develop and deploy centrifuge technology to produce enriched uranium for commercial and government uses, including for national security.

ASND vs LEU — Head-to-Head

Bigger by revenue
ASND
ASND
1.8× larger
ASND
$267.3M
$146.2M
LEU
Growing faster (revenue YoY)
ASND
ASND
+45.9% gap
ASND
42.3%
-3.6%
LEU
Faster 2-yr revenue CAGR
LEU
LEU
Annualised
LEU
82.9%
60.7%
ASND

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASND
ASND
LEU
LEU
Revenue
$267.3M
$146.2M
Net Profit
Gross Margin
90.5%
23.9%
Operating Margin
8.8%
Net Margin
Revenue YoY
42.3%
-3.6%
Net Profit YoY
EPS (diluted)
$0.52

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASND
ASND
LEU
LEU
Q4 25
$267.3M
$146.2M
Q3 25
$230.7M
$74.9M
Q2 25
$170.7M
$154.5M
Q1 25
$109.0M
$73.1M
Q4 24
$187.8M
$151.6M
Q3 24
$62.5M
$57.7M
Q2 24
$38.9M
$189.0M
Q1 24
$103.6M
$43.7M
Net Profit
ASND
ASND
LEU
LEU
Q4 25
Q3 25
$-65.9M
$3.9M
Q2 25
$-42.0M
$28.9M
Q1 25
$-102.2M
$27.2M
Q4 24
Q3 24
$-107.1M
$-5.0M
Q2 24
$-118.1M
$30.6M
Q1 24
$-141.5M
$-6.1M
Gross Margin
ASND
ASND
LEU
LEU
Q4 25
90.5%
23.9%
Q3 25
89.5%
-5.7%
Q2 25
80.1%
34.9%
Q1 25
82.6%
45.0%
Q4 24
91.9%
40.8%
Q3 24
80.6%
15.4%
Q2 24
68.2%
19.3%
Q1 24
92.1%
9.8%
Operating Margin
ASND
ASND
LEU
LEU
Q4 25
8.8%
Q3 25
5.1%
-22.2%
Q2 25
-33.5%
21.7%
Q1 25
-103.2%
28.0%
Q4 24
29.7%
Q3 24
-167.3%
-13.2%
Q2 24
-370.2%
11.2%
Q1 24
-51.2%
-24.3%
Net Margin
ASND
ASND
LEU
LEU
Q4 25
Q3 25
-28.5%
5.2%
Q2 25
-24.6%
18.7%
Q1 25
-93.7%
37.2%
Q4 24
Q3 24
-171.5%
-8.7%
Q2 24
-303.9%
16.2%
Q1 24
-136.6%
-14.0%
EPS (diluted)
ASND
ASND
LEU
LEU
Q4 25
$0.52
Q3 25
$0.19
Q2 25
$1.59
Q1 25
$1.60
Q4 24
$3.26
Q3 24
$-0.30
Q2 24
$1.89
Q1 24
$-0.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASND
ASND
LEU
LEU
Cash + ST InvestmentsLiquidity on hand
$665.3M
$2.0B
Total DebtLower is stronger
$1.2B
Stockholders' EquityBook value
$-175.8M
$765.1M
Total Assets
$1.4B
$2.4B
Debt / EquityLower = less leverage
1.54×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASND
ASND
LEU
LEU
Q4 25
$665.3M
$2.0B
Q3 25
$582.2M
$1.6B
Q2 25
$533.6M
$833.0M
Q1 25
$559.4M
$653.0M
Q4 24
$604.3M
$671.4M
Q3 24
$675.6M
$194.3M
Q2 24
$279.4M
$227.0M
Q1 24
$345.9M
$209.3M
Total Debt
ASND
ASND
LEU
LEU
Q4 25
$1.2B
Q3 25
$1.2B
Q2 25
$390.0M
Q1 25
$389.5M
Q4 24
$472.5M
Q3 24
$83.5M
Q2 24
$86.5M
Q1 24
$86.5M
Stockholders' Equity
ASND
ASND
LEU
LEU
Q4 25
$-175.8M
$765.1M
Q3 25
$-188.0M
$363.1M
Q2 25
$-202.6M
$359.1M
Q1 25
$-205.0M
$213.9M
Q4 24
$-114.2M
$161.4M
Q3 24
$-105.1M
$76.4M
Q2 24
$-346.8M
$76.6M
Q1 24
$-257.2M
$33.8M
Total Assets
ASND
ASND
LEU
LEU
Q4 25
$1.4B
$2.4B
Q3 25
$1.2B
$2.2B
Q2 25
$1.2B
$1.3B
Q1 25
$1.1B
$1.3B
Q4 24
$1.3B
$1.1B
Q3 24
$1.2B
$591.0M
Q2 24
$819.0M
$668.2M
Q1 24
$866.7M
$750.0M
Debt / Equity
ASND
ASND
LEU
LEU
Q4 25
1.54×
Q3 25
3.23×
Q2 25
1.09×
Q1 25
1.82×
Q4 24
2.93×
Q3 24
1.09×
Q2 24
1.13×
Q1 24
2.56×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASND
ASND
LEU
LEU
Operating Cash FlowLast quarter
$58.2M
$-48.4M
Free Cash FlowOCF − Capex
$-58.0M
FCF MarginFCF / Revenue
-39.7%
Capex IntensityCapex / Revenue
6.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$31.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASND
ASND
LEU
LEU
Q4 25
$58.2M
$-48.4M
Q3 25
$10.1M
Q2 25
$52.8M
Q1 25
$-15.5M
$36.5M
Q4 24
$-330.7M
$57.9M
Q3 24
$-33.2M
Q2 24
$7.0M
Q1 24
$-109.7M
$5.3M
Free Cash Flow
ASND
ASND
LEU
LEU
Q4 25
$-58.0M
Q3 25
$5.7M
Q2 25
$49.2M
Q1 25
$34.4M
Q4 24
$57.2M
Q3 24
$-34.2M
Q2 24
$6.1M
Q1 24
$3.8M
FCF Margin
ASND
ASND
LEU
LEU
Q4 25
-39.7%
Q3 25
7.6%
Q2 25
31.8%
Q1 25
47.1%
Q4 24
37.7%
Q3 24
-59.3%
Q2 24
3.2%
Q1 24
8.7%
Capex Intensity
ASND
ASND
LEU
LEU
Q4 25
6.6%
Q3 25
5.9%
Q2 25
2.3%
Q1 25
2.9%
Q4 24
0.5%
Q3 24
1.7%
Q2 24
0.5%
Q1 24
3.4%
Cash Conversion
ASND
ASND
LEU
LEU
Q4 25
Q3 25
2.59×
Q2 25
1.83×
Q1 25
1.34×
Q4 24
Q3 24
Q2 24
0.23×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASND
ASND

Segment breakdown not available.

LEU
LEU

Separative Work Units$111.0M76%
Services$21.8M15%
Other$13.4M9%

Related Comparisons